Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene LtdfiledCriticalBeigene Ltd
Priority to SG10201810284VApriorityCriticalpatent/SG10201810284VA/en
Publication of SG10201810284VApublicationCriticalpatent/SG10201810284VA/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
ANTI-PD1 ANTmODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICS Provided are antibodies that specifically bind to Programmed Death-I (PD I, Pdcd-I, or CD279) and inhibit PD I-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PDI- mediated functions. Figure for publication: None
SG10201810284VA2013-09-132013-09-13Anti-pd1 antibodies and their use as therapeutics and diagnostics
SG10201810284VA
(en)